Combining two medications for treating postmenopausal osteoporosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of two FDA-approved medications, Romosozumab and Teriparatide, on women suffering from postmenopausal osteoporosis. The study aims to determine the efficacy of these combined anabolic therapies in improving bone health and reducing fracture risk. Participants will be closely monitored to assess the outcomes of the treatment regimen over time. The trial is designed for women aged 45 and older who are at high risk for fractures due to osteoporosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* women aged 45+
* postmenopausal
* osteoporotic with high risk of fracture

Exclusion Criteria:

* no significant previous use of bone health modifying treatments
* known congenital or acquired bone disease other than osteoporosis
* significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
* abnormal calcium or parathyroid hormone level
* serum vitamin D \<20 ng/dL
* anemia (hematocrit \<32%)
* history of malignancy (except non-melanoma skin carcinoma)
* excessive alcohol use or substance abuse
* known contraindications to romosozumab or teriparatide

Where it's running

• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Benjamin Leder, MD — Mgh
• Study coordinator: Aparna Patnaik, BA
• Email: apatnaik1@mgh.harvard.edu
• Phone: 617-726-6129

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing two treatment regimens for osteoporosis in postmenopausal women

  This study is testing two different treatment plans for osteoporosis in postmenopausal women to see which one helps improve bone strength and reduce the risk of fractures better.

  Recruiting Phase 4 National Taiwan University Hospital · Taipei · NCT06938152

• Role of LH and hCG in adults being evaluated for endocrine disorders

  This study looks at whether levels of luteinizing hormone (LH) and hCG in adults undergoing endocrine evaluation relate to their disease presence and outcomes.

  Recruiting Copenhagen University Hospital at Herlev · Herlev · NCT07824102

• Can a blood marker called lumican reveal hidden fragility in postmenopausal osteoporosis

  This study tests whether serum lumican levels can help identify hidden fragility risk in postmenopausal women beyond what bone density shows.

  Recruiting Kanuni Sultan Suleyman Training and Research Hospital · Küçükçekmece, Istanbul · NCT07677072

• Functional Muscle-Bone Incongruity Index: A look at muscle strength and bone health in adults

  This observational study tests a composite FKUI score using handgrip strength and hip/spine bone density to see if it better reflects musculoskeletal health than each measure alone in adults undergoing routine DXA.

  Recruiting Kanuni Sultan Suleyman Training and Research Hospital · Küçükçekmece, Istanbul · NCT07677033

• Vessel-X Bone Filling Container System for Vertebral Augmentation

  A new minimally invasive vertebral augmentation approach tests the Vessel-X device to see if it safely improves pain and function in people with osteoporotic vertebral compression fractures.

  Recruiting at 2 sites National Defense Medical Center, Taiwan · Taipei and 1 other locations · NCT07665424

• Proximal Humerus Cortical Thickness in Post-Stroke Paresis

  This study tests whether measurements of the outer bone thickness of the upper arm (the humerus) on the paretic side after a stroke reflect regional bone loss and how well they agree with standard bone density tests.

  Recruiting Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Istanbul · NCT07651306

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.